Protalix BioTherapeutics Income Statement 2025-2008 | PLX

Brief overview of revenue and earnings at Protalix BioTherapeutics

This overview is based on financial performance over the past five years. According to figures from Protalix BioTherapeutics, revenue changed from 62.9 million dollars to 52.7 million dollars over five years. The total change was −16.1%, with a CAGR of approximately −3.5%. Sales followed a declining trajectory over the five years.

Gross profit was $52 million at the start and $25.8 million at the end of the period (−50.5%). The cost base moved against the top-line trend and weighed on the gross result. The gross margin was 82.7% at the start and 48.8% at the end. The business retained less gross profit from each unit of revenue.

The operating result measured by EBITDA moved from 4 million dollars to −4 million dollars, or −200.6%. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 6.4% at the start and −7.7% at the end. Cost pressure reduced operating profitability.

Across the five years, the net result shifted from −6.5 million dollars to −6.6 million dollars. Larger losses indicate rising pressure on the business.

Market value was 128 million dollars at the start and 174 million dollars at the end. Market value supported the favorable financial trajectory.

Overall conclusion

The indicators point to a weaker financial profile. The positive side is supported by consistent net profitability. The weaker side of the profile includes pressure on operating profitability, a softer top-line trend and a narrow EBITDA buffer. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.